Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

PLGA-based herb Toosendanin delivery system for efficient therapy of oral squamous cell carcinoma.

Created on 02 Sep 2026

Authors

Lingling Chen, Cheng Feng, Zhenyu Shi, Jianzhe Wang, Tao Wang, Yibing Wang, Lisong Lin, Ye Wu

Published in

BMC complementary medicine and therapies. Volume 25. Issue 1. Pages 217. Jul 02, 2025. Epub Jul 02, 2025.

Abstract

Oral squamous cell carcinoma (OSCC) is a significant public health issue worldwide. Conventional chemotherapeutic agents do not adequately meet the treatment demands because of their low efficacy and adverse side effects. Toosendanin (TSN) is a natural extract with potential anticarcinogenic activity. Nonetheless, its clinical application is constrained by its poor water-solubility and limited bioavailability. Therefore, we prepared TSN-loaded poly (lactic-co-glycolic acid) nanoparticles (TSN-PLGA NPs) to improve the water-solubility of TSN and potentially further enhance its bioavailability. TSN-PLGA NPs were synthesized and characterized, and we showed their exceptional properties for sustained release in vitro. TSN-PLGA NPs exhibited cytotoxic effects against OSCC cells, potentially inhibiting proliferation and promoting apoptosis by inducing cell-cycle arrest in the S-phase at low concentrations. RNA-sequencing analysis revealed the potential regulation of OSCC cell viability by TSN-PLGA NPs through signaling pathways such as JAK/STAT and PI3K-Akt. Furthermore, animal models provided evidence of the in vivo antitumor activity of TSN-PLGA NPs, with no observable side effects in nude mice, which indicated potential biocompatibility. Consequently, TSN-PLGA NPs may be a promising chemotherapy candidate for OSCC treatment.

PMID:
40604940
Bibliographic data and abstract were imported from PubMed on 02 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement